Skip to main
ARDX

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx is well positioned for long-term growth, with successful commercial execution on both IBSRELA and XPHOZAH and the potential additional revenue streams from label expansions and new indications in CIC. The company's strong financial position, with a reported $264.7 million in cash and equivalents, allows it to invest in the future growth of its pipeline and continue to innovate in the biopharmaceutical market. The recent patent approval and commencement of dosing in a Phase 3 trial for IBSRELA in CIC also add to the company's long-term potential.

Bears say

Ardelyx is facing potential risks, such as failure to execute commercially and increasing competition from generic and branded players, which could impact shares. Additionally, while Ardelyx has a significant opportunity in the 2L market for IBS-C, with limited competition for its non-secretagogue drug Ibsrela, there is also a risk of competitors emerging in the future. Furthermore, while current specialty pharmacy relationships are crucial for driving performance, retail pharmacies may be less incentivized to fill prescriptions for non-generic drugs.

Ardelyx (ARDX) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Ardelyx (ARDX) has a Strong Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.